Cd38 pe

Manufactured by Exbio

Sourced in Czechia

CD38-PE is a laboratory reagent used for the detection and analysis of CD38 expression on cell surfaces. It consists of a monoclonal antibody conjugated to the fluorescent dye phycoerythrin (PE), which allows for the identification and quantification of CD38-positive cells in various applications, such as flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Cd8 buv395, by BD (2 mentions) Cd45 v450, by BD (2 mentions) Cd19 buv737, by BD (2 mentions) Cd34 bv786, by BD (2 mentions) Cd4 buv395, by BD (2 mentions) Histopaque 1077, by Merck Group (2 mentions) Cd123 buv395, by BD (1 mentions) Pd l2 apc, by Thermo Fisher Scientific (1 mentions) Hla dr fitc, by Thermo Fisher Scientific (1 mentions) Tim3 apc, by Thermo Fisher Scientific (1 mentions) Lightning link fluorescein conjugation kit, by Abcam (1 mentions)

2 protocols using cd38 pe

Immunophenotyping of AML Leukapheresis Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mononuclear cells from the peripheral blood of 36 patients with AML indicated at leukapheresis due to hyperleukocytosis at diagnosis were obtained by separation of leukapheretic products on Histopaque 1077 (Sigma, Prague, Czech Republic). The cells were resuspended in RPMI 1640 medium with 10% fetal calf serum and with antibiotics (100 U/mL penicillin, 100 µg/mL streptomycin), and aliquots were used for RNA isolation and for analysis of surface markers by flow cytometry. Additional analyses of PD-L1 transcripts were performed from cDNA samples, which had been taken for routine clinical analyses and cryopreserved. A written informed consent with the use of biological material for research purposes was obtained from all patients. The study was approved by the Ethics Committee of the Institute of Hematology and Blood Transfusion of the Czech Republic as a part of the research project 16-30268A (June 2015).
Antibodies used were the following: CD45-V450 (#560367), CD4-BUV395 (#564724), CD8-BUV395 (#563795), CD19-BUV737 (#564303), CD123-BUV395 (#564195), CD371(CLL-1)-BB515 (#565926), CD135(FLT3)-AlexaFluor647 (#563494), and CD34-BV786 (#743534) were from BD Biosciences (Prague, Czech Republic); CD38-PE (#1P-366-T100) from Exbio (Prague, Czech Republic); PD-1-APC (#17-2799-42) and PD-L1-PE-Cy7 (#25-5983-42) from Affymetrix, Inc. (San Diego, CA, USA).

Brodská B., Otevřelová P., Šálek C., Fuchs O., Gašová Z, & Kuželová K. (2019). High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. International Journal of Molecular Sciences, 20(11), 2823.

+ Open protocol

+ Expand

Phenotyping Leukemic Cells from AML Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary cells from peripheral blood of AML patients with hyperleukocytosis were obtained by leukapheresis before therapy initiation. The leukapheretic products were diluted 10-fold in phosphate buffered saline (PBS), and the mononuclear cell fraction was separated using Histopaque-1077 (Sigma, #H8889). The cells were resuspended in RPMI 1640 medium with 10% fetal calf serum and with antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin), and aliquots were used for analysis of surface markers by flow cytometry and for mRNA isolation.
The antibodies used were as follows: CD45-V450 (#560367), CD4-BUV395 (#564724), CD8-BUV395 (#563795), CD19-BUV737 (#564303), CD34-BV786 (#743534), and CD371-BB515 (#565926) from BD Biosciences; HLA-DR-FITC (#11-9952-42), TIM-3-APC (#17-3109-42), and PD-L2-APC (#17-5888-42) from eBioscience; CLIP-PE (sc-12725 PE) from Santa Cruz; PD-L1-PE (#1P-177-T100), CD47-FITC (#1F-225-T100), and CD38-PE (#1P-366-T100) from Exbio (Prague, Czech Republic). HLA class I antibody (Abcam, ab2217) was conjugated in house using the Lightning-Link Fluorescein Conjugation kit (#707-0010, Innova Biosciences).

Kuželová K., Brodská B., Marková J., Petráčková M., Schetelig J., Ransdorfová Š., Gašová Z, & Šálek C. (2022). NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia. Oncoimmunology, 11(1), 2073050.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!